Navigation Links
Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
Date:9/24/2007

PITTSBURGH, Sept. 24 /PRNewswire/ -- Knopp Neurosciences Inc. ("Knopp") today announced the initiation of a Phase 1 clinical trial of KNS-760704, a small molecule therapy in development for the treatment of amyotrophic lateral sclerosis (ALS).

(Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO )

This randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers is being closely followed by a multiple ascending dose study in healthy subjects. Both studies are designed to evaluate the safety, tolerability and pharmacokinetics of KNS-760704 in human subjects.

"The initiation of Phase 1 represents a significant milestone in Knopp's efforts to develop a safe and effective therapy for a serious unmet medical need," said Michael Bozik, M.D., president and chief executive officer of Knopp. "We look forward to completing these safety studies and moving rapidly to advance the compound into initial clinical trials in ALS patients."

About KNS-760704

KNS-760704 is an orally administered small molecule in clinical development by Knopp for the treatment of amyotrophic lateral sclerosis (ALS). The drug is an optical enantiomer of a selective, high affinity dopamine agonist marketed in other neurological indications. Both KNS-760704 and the marketed agonist demonstrate neuroprotective properties independent of dopamine receptor activity, but KNS-760704 exhibits greatly reduced dopamine receptor affinity. This makes it possible to clinically evaluate the potential neuroprotective activity of KNS-760704 over a broad dose range.

About ALS

Amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease, is a rapid, universally fatal neurodegenerative disorder characterized by progressive muscle weakness and wasting. ALS affects adults in the prime of life and creates a substantial burden for caregivers. U.S. prevalence is nearly 30,000 and the incidence is 1.2 per 100,000. Only a single drug has been approved for the treatment of ALS. Life expectancy after symptom onset is usually three to five years.

About Knopp Neurosciences Inc. (http://www.knoppneurosciences.com)

Knopp Neurosciences is a drug discovery and development company focused on delivering breakthrough treatments for neurological disorders through innovation, experience, and partnership. The company's lead product candidate is KNS-760704, an orally bioavailable small molecule in development for the treatment of ALS. Knopp's leadership includes experienced neuroscience drug development and discovery executives formerly associated with major pharmaceutical companies. Knopp's financing has been led Saturn Capital Inc. of Boston as placement agent and Saturn Partners II as lead funder.

This press release contains "forward-looking statements," including statements relating to Knopp's planned regulatory filings and clinical development programs for KNS-760704. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that KNS-760704 will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the products. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Knopp Neurosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... Elekta today announced that its ... the focal point of seven scientific presentations at ESTRO ... Radiotherapy & Oncology, taking place April 29 - May ... system and a high-field MRI scanner with sophisticated software ... anatomy in real time. The MR-linac is designed to ...
(Date:4/27/2016)... , April 27, 2016  Bayer Animal Health ... senior from the University of Florida College of ... Bayer Excellence in Communication Award (BECA). Brittany was ... were awarded a total of $70,000 in scholarship ... four years, Bayer has provided a total of ...
(Date:4/27/2016)... FRANCISCO , April 27, 2016 ... reach over USD 2.14 billion by 2022, according ... Inc.       (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... technological advancement affecting the efficiency and accuracy delivered ... the persistent demand for novel urinalysis instruments and ...
Breaking Medicine Technology:
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Dr. ... cosmetic dental treatments to improve smiles. Cosmetic dentistry is a fast-growing field as more ... This offer allows patients to learn more about the options currently available to them ...
(Date:4/29/2016)... Grants Pass, OR (PRWEB) , ... April 29, 2016 , ... ... nutritionists suggest dinner as the meal to miss. That was among the many new ... True Nutrition, on a recent Sharon Kleyne Hour® Power of Water® radio show. Bonny ...
(Date:4/29/2016)... ... ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of 100 on Tampa ... for Tampa’s Best Places to Work. They were ranked in the Big Category, which ... our team,” says RMS Human Resources Manager Irene Miller. “We work hard to build ...
(Date:4/29/2016)... ... , ... Nike Softball Camp at the College of Brockport in New York ... aged 10-18. All facets of the game will be covered; hitting, fielding, base-running, and ... of the finest softball facilities in the region. The outstanding professional college staff complement ...
(Date:4/29/2016)... ... April 29, 2016 , ... HEALTHCAREfirst ... and coding services, and Deyta Analytics, recently announced the recipients of the fourth ... of quality as measured from the caregiver’s point of view. The official list ...
Breaking Medicine News(10 mins):